Affiliations: [a] Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, China | [b] Peking University Health Science Center, Beijing, China | [c] Department of Otolaryngology, Peking University People’s Hospital, Beijing, China | [d] Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing, China
Correspondence:
[*]
Corresponding authors: Lin Fu, Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, 49 North Garden Rd., Haidian District, Beijing 100191, China. Tel./Fax: +86 10 8226 7651; E-mail: fulin022@126.com; Xiaoyan Ke, Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, 49 North Garden Rd., Haidian District, Beijing 100191, China. Tel./Fax: +86 10 8226 7651; E-mail: xykbysy@163.com.
Abstract: BACKGROUND: ACOT plays an important role in lipid metabolism and recent studies found that ACOT participates in some kinds of tumorigenesis. However, both the role of ACOT and its significance have not been revealed in AML. Therefore, we conduct this study in order to investigate the association between AML and ACOT, and hopefully contributed to the management of AML. METHODS: One hundred and fifty-six AML patients were enrolled in our study whose data were derived from the Cancer Genome Atlas database. There were 85 patients who received only chemotherapy and other 71 patients underwent allo-HSCT. RESULTS: Patients in high ACOT7 group had a significant lower EFS and OS, while patients in high versus low expression levels of other types of ACOT showed no significant difference on the outcome. High level of ACOT7 related with poor outcome in both chemotherapy-only group and HSCT group. CONCLUSIONS: High expression level of ACOT7 indicates unfavorable outcome in AML patients. Allo-HSCT could not overcome the unfavorable effect of ACOT7 in these patients.
